Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China Nonprescription Medicines Association Releases 2008 OTC Sales Ranking List

This article was originally published in PharmAsia News

Executive Summary

At the recent China Self-Medication Annual Meeting, China's Nonprescription Medicines Association released its annual statistics and survey results of the local OTC businesses. Xiuzheng Pharmaceutical Group, Xian-Janssen, Harbin Pharmaceutical Group, Sanjiu Medical & Pharmaceutical and TSKF are listed as the five companies with biggest sales in 2008. For OTC chemical drugs, TSKF's Fenbid, Bayer's Saridon, Shanghai Johnson & Johnson's Motrin and Tylenol, and HPG's Anruike garnered the top spots. TSKF's new Contac and Bayer's White & Black were among the top five for cold and cough; Wyeth's Caltrate D and Bayer'sRedoxon for vitamins and minerals; Xian-Janssen's Motilium and Bayer's Talcid for digestives; and Xian-Janssen's Daktarin and Pevisone for external use agents. Local products dominated in patent TCM, surgery and women's health sectors. (Click here for more - Chinese language)

You may also be interested in...

Lannett Reports Insulin Glargine Trial Success

Lannett’s Phase I trial for biosimilar insulin glargine has met “all primary endpoints,” the company has announced. The rival to Sanofi’s Lantus is being developed by Lannett with partner HEC through a deal for which financial details have just been revealed.

BREAKING: Sanofi Forms Standalone Consumer Healthcare Unit: Prelude To Spin-Off?

Sanofi Consumer Healthcare is to operate as a standalone unit in a move which is being viewed as a prelude to a potential spin-off. High profile prescription-to-OTC switches are a priority for the revamped business. 

Data Integrity Remains Challenging For API Manufacturers

Data integrity issues were raised in many warning letters to active pharmaceutical ingredient manufacturers over the past four years.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts